```html

Flagship-Founded Quotient Collaborates with Pfizer

A Promising Partnership for Drug Discovery

Flagship-Founded Quotient and Pfizer Embark on a Joint Venture

Quotient Therapeutics, a biotechnology company co-founded by Flagship Pioneering, has forged a strategic collaboration with pharmaceutical giant Pfizer.

This partnership will leverage Quotient's proprietary drug discovery platform, which combines gene editing, high-throughput screening, and machine learning, with Pfizer's extensive expertise in drug development and commercialization.

Unveiling New Therapeutic Frontiers

The collaboration aims to accelerate the discovery and development of novel therapeutics for a wide range of diseases.

By combining Quotient's platform with Pfizer's resources, the partnership seeks to:

• Identify new drug targets
• Develop more effective and safer treatments
• Bring therapies to market faster

A Shared Commitment to Innovation

The collaboration underscores Quotient's position as a leader in drug discovery and Pfizer's dedication to delivering innovative medicines to patients.

Together, the companies will harness their combined scientific expertise and technological capabilities to push the boundaries of drug development.

Additional Information and Sources:

Pfizer Press Release Quotient Therapeutics Flagship Pioneering ```